We are live on ! Find out more
CC

Commodore Capital Portfolio holdings

AUM $1.73B
1-Year Est. Return 298.96%
This Fund
S&P 500
This Quarter Est. Return
+18.68%
1 Year Est. Return
+298.96%
3 Year Est. Return
+2,048.53%
5 Year Est. Return
+6,668.48%
10 Year Est. Return
–
AUM
$432M
AUM Growth
+$52.5M
Cap. Flow
+$99.1M
Cap. Flow %
22.96%
Top 10 Hldgs %
72.69%
Holding
32
New
3
Increased
10
Reduced
2
Closed
7

Top Buys

Rank Stock Value
1
ALLK
Allakos
ALLK
+$66.8M
2
MRUS
Merus
MRUS
+$22.1M
3
BLU
BELLUS Health Inc.
BLU
+$20.7M
4
XENE icon
Xenon Pharmaceuticals
XENE
+$15.3M
5
PTGX icon
Protagonist Therapeutics
PTGX
+$9.72M

Top Sells

Rank Stock Value
1
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
+$26.1M
2
KURA icon
Kura Oncology
KURA
+$18.7M
3
CLDX icon
Celldex Therapeutics
CLDX
+$13.4M
4
IOVA icon
Iovance Biotherapeutics
IOVA
+$8.95M
5
RVMD icon
Revolution Medicines
RVMD
+$6.22M

Sector Composition

Rank Sector Weight
1 Healthcare 99.43%
2 Financials 0.57%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ATXS
26
DELISTED
Astria Therapeutics
ATXS
– –
-239,270
Closed -$2.12M
CLDX icon
27
Celldex Therapeutics
CLDX
$2.77B
– –
-248,207
Closed -$13.4M
IOVA icon
28
Iovance Biotherapeutics
IOVA
$2.23B
– –
-362,869
Closed -$8.95M
KURA icon
29
Kura Oncology
KURA
$922M
– –
-999,433
Closed -$18.7M
RVMD icon
30
Revolution Medicines
RVMD
$40.2B
– –
-226,228
Closed -$6.22M
SPRY icon
31
ARS Pharmaceuticals
SPRY
$590M
– –
-97,143
Closed -$969K
DRNA
32
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
– –
-1,292,251
Closed -$26.1M
1
2

Similar funds

RIA
Regal Investment Advisors Kentwood, Michigan $1.73B AUM 17.74% 1-Year Est. Return
PAIM
Punch & Associates Investment Management Edina, Minnesota $1.73B AUM 27.65% 1-Year Est. Return
MCWS
McKinley Carter Wealth Services Wheeling, West Virginia $1.73B AUM 17.28% 1-Year Est. Return
VCA
Verdence Capital Advisors Hunt Valley, Maryland $1.72B AUM 24.88% 1-Year Est. Return
ESBC
E.S. Barr & Co Lexington, Kentucky $1.72B AUM 12.69% 1-Year Est. Return
MSR
Main Street Research Lakeville, Connecticut $1.72B AUM 48.78% 1-Year Est. Return
WJA
Willis Johnson & Associates Houston, Texas $1.72B AUM 16.93% 1-Year Est. Return
OMC
Oasis Management Company Grand Cayman, Cayman Islands $1.72B AUM 32.1% 1-Year Est. Return

Commodore Capital's Q4 2021 Portfolio in Review

As of Q4 2021, Commodore Capital held 32 positions worth $432M, up 14% from $379M the previous quarter. Its ten largest holdings account for 73% of the portfolio.

Commodore Capital deployed $99.1M of net new capital in Q4 2021, opening 3 new positions and adding to 10 existing holdings. Its largest new stake was Allakos: 815,667 shares worth $7.99M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 92% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Cytokinetics, an estimated $3.55M trimmed.

  • Commodore Capital's largest Q4 2021 buy was Allakos: 815,667 shares worth $7.99M.
  • Commodore Capital added most to Merus in Q4 2021, an estimated $22.1M increase.
  • Commodore Capital's biggest Q4 2021 reduction was Cytokinetics, cutting an estimated $3.55M.
  • Commodore Capital fully exited Dicerna Pharmaceuticals, Inc. in Q4 2021, selling an estimated $26.1M.
  • Commodore Capital's ten largest holdings make up 73% of its $432M portfolio in Q4 2021.
  • Commodore Capital opened 3 new positions and closed 7 in Q4 2021.
  • Commodore Capital's portfolio value rose 14% quarter-over-quarter to $432M.

Based on Commodore Capital's 13F filing for Q4 2021, filed 14 Feb 2022.